Abstract
Mutations within the gene for the hepatic enzyme phenylalanine hydroxylase (PAH) and those involving enzymes of pterin metabolism are associated with hyperphenylalaninaemia (HPA). Phenylketonuria (PKU) is caused by a severe deficiency in PAH activity and if left untreated leads to permanent central nervous system damage. Dietary restriction of phenylalanine (PHE) along with amino acid, vitamin and mineral supplements, started in the first weeks of life and continued through childhood, is an effective treatment and allows for normal cognitive development.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
References
Guldberg P, Rey F, Zschocke J et al. (1998) A European multicenter study of phenylalanine hydroxylase deficiency: classification of 105 mutations and a general system for genotype-based prediction of metabolic phenotype. Am J Hum Genet 63:71–79
Scriver C, Levy H, Donlon J (2001) Hyperphenylalaninaemia: phenylalanine hydroxylase deficiency. In: Valle D, Beaudet AL, Vogelstein B et al. (eds) Metabolic and molecular bases of inherited disease, 8th edn, updated April 2008. McGraw-Hill, New York
Ahring K, Belanger-Quintana A, Dokoupil K et al. (2009) Dietary management practices in phenylketonuria across European centres. Clin Nutr 28:231–236
Anonymous (1993) Phenylketonuria due to phenylalanine hydroxylase deficiency: an unfolding story. Medical Research Council Working Party on Phenylketonuria. BMJ 306:115–119
Burgard P, Bremer HJ, Buhrdel P et al. (1999) Rationale for the German recommendations for phenylalanine level control in phenylketonuria 1997. Eur J Pediatr 158:46–54
Anonymous (2001) American Academy of Pediatrics: Maternal phenylketonuria. Pediatrics 107:427–428
Abadie V, Berthelot J, Feillet F et al. (2005) [Management of phenylketonuria and Hyperphenylalaninaemia: the French guidelines]. Arch Pediatr 12:594–601
Bekhof J, Rijn v M, Sauer PJ et al. (2005) Plasma phenylalanine in patients with phenylketonuria self-managing their diet. Arch Dis Child 90:163–164
Kure S, Hou DC, Ohura T et al. (1999) Tetrahydrobiopterin-responsive phenylalanine hydroxylase deficiency. J Pediatr 135:375–378
Lindner M, Gramer G, Garbade SF et al. (2009) Blood phenylalanine concentrations in patients with PAH-deficient hyperphenylalaninaemia off diet without and with three different single oral doses of tetrahydrobiopterin: assessing responsiveness in a model of statistical process control. J Inherit Metab Dis 32:514–522
Gersting SW, Kemter KF, Staudigl M et al. (2008) Loss of function in phenylketonuria is caused by impaired molecular motions and conformational instability. Am J Hum Genet 83:5–17
Gersting SW, Lagler FB, Eichinger A et al. (2010) Pahenu1 is a mouse model for tetrahydrobiopterin-responsive phenylalanine hydroxylase deficiency and promotes analysis of the pharmacological chaperone mechanism in vivo. Hum Mol Genet 19:2039–2049
Sanford M, Keating GM (2009) Sapropterin: a review of its use in the treatment of primary hyperphenylalaninaemia. Drugs 69:461–476
Antoshechkin AG, Chentsova TV, Tatur V et al. (1991) Content of phenylalanine, tyrosine and their metabolites in CSF in phenylketonuria. J Inherit Metab Dis 14:749–754
Somaraju UR, Merrin M (2010) Sapropterin dihydrochloride for phenylketonuria. Cochrane Database Syst Rev 6:CD008005
Anonymous (2010) Kuvan: summary of product characteristics. http://www.ema.europa.eu/ema/index.jsp?curl=pages/medicines/human/medicines/000943/human_med_000880.jsp&mid=WC0b01ac058001d124&murl=menus/medicines/medicines.jsp&jsenabled=true
Ding Z, Harding CO, Thony B (2004) State-of-the-art 2003 on PKU gene therapy. Mol Genet Metab 81:3–8
Vajro P, Strisciuglio P, Houssin D et al. (1993) Correction of phenylketonuria after liver transplantation in a child with cirrhosis. N Engl J Med 329:363
Harding CO, Gibson KM (2010) Therapeutic liver repopulation for phenylketonuria. J Inherit Metab Dis 336:681–687
Koch R, Moseley KD, Yano S et al. (2003) Large neutral amino acid therapy and phenylketonuria: a promising approach to treatment. Mol Genet Metab 79:110–113
Matalon R, Michals-Matalon K, Bhatia G et al. (2006) Large neutral amino acids in the treatment of phenylketonuria (PKU). J Inherit Metab Dis 29:732–738
Schindeler S, Ghosh-Jerath S, Thompson S et al. (2007) The effects of large neutral amino acid supplements in PKU: an MRS and neuropsychological study. Mol Genet Metab 91:48–54
Burgard P, Schmidt E, Rupp A et al. (1996) Intellectual development of the patients of the German Collaborative Study of children treated for phenylketonuria. Eur J Pediatr 155 [Suppl 1]:S33–38
Walter JH, White FJ, Hall SK et al. (2002) How practical are recommendations for dietary control in phenylketonuria? Lancet 360:55–57
Smith I, Beasley MG, Ades AE (1990) Intelligence and quality of dietary treatment in phenylketonuria. Arch Dis Child 65:472–478
Smith I, Beasley MG, Ades AE (1991) Effect on intelligence of relaxing the low phenylalanine diet in phenylketonuria. Arch Dis Child 66:311–316
Burgard P, Link R, Schweitzer-Krantz S (2000) The effect of a phenylalanine-restricted diet on phenylketonuria. Eur J Pediatr 159 [Suppl 2]:S69
Lundstedt G, Johansson A, Melin L et al. (2001) Adjustment and intelligence among children with phenylketonuria in Sweden. Acta Paediatr 90:1147–1152
Poustie VJ, Wildgoose J (2010) Dietary interventions for phenylketonuria. Cochrane Database Syst Rev:CD001304
Bosch AM, Tybout W, Spronsen v FJ et al. (2007) The course of life and quality of life of early and continuously treated Dutch patients with phenylketonuria. J Inherit Metab Dis 30:29–34
Simon E, Schwarz M, Roos J et al. (2008) Evaluation of quality of life and description of the sociodemographic state in adolescent and young adult patients with phenylketonuria (PKU). Health Qual Life Outcomes 6:25
Welsh M, Pennington B (2000) Phenylketonuria. In: Yeats KO, Ris, MD, Taylor HG (eds) Pediatric neuropsychology. Guildford Press, New York, pp 275–299
Moyle JJ, Fox AM, Arthur M et al. (2007) Meta-analysis of neuropsychological symptoms of adolescents and adults with PKU. Neuropsychol Rev 17:91–101
Albrecht J, Garbade SF, Burgard P (2009) Neuropsychological speed tests and blood phenylalanine levels in patients with phenylketonuria: a meta-analysis. Neurosci Biobehav Rev 33:414–421
Cleary MA, Walter JH, Wraith JE et al. (1995) Magnetic resonance imaging in phenylketonuria: reversal of cerebral white matter change. J Pediatr 127:251–255
Feldmann R, Denecke J, Pietsch M et al. (2002) Phenylketonuria: no specific frontal lobe-dependent neuropsychological deficits of early-treated patients in comparison with diabetics. Pediatr Res 51:761–765
Thompson AJ, Smith I, Brenton D et al. (1990) Neurological deterioration in young adults with phenylketonuria. Lancet 336:602–605
Lee P, Smith I, Piesowicz A et al. (1999) Spastic paraparesis after anaesthesia. Lancet 353:554
Robinson M, White FJ, Cleary MA et al. (2000) Increased risk of vitamin B12 deficiency in patients with phenylketonuria on an unrestricted or relaxed diet. J Pediatr 136:545–547
Koletzko B, Beblo S, Demmelmair H et al. (2009) Does dietary DHA improve neural function in children? Observations in phenylketonuria. Prostaglandins Leukot Essent Fatty Acids 81:159–164
Lee PJ, Amos A, Robertson L et al. (2009). Adults with late diagnosed PKU and severe challenging behaviour: a randomized placebo-controlled trial of a phenylalanine-restricted diet. J Neurol Neurosurg Psychiatry 80: 631–635
Mabry CC, Denniston JC, Nelson TL et al. (1963) Maternal phenylketonuria. A cause of mental retardation in children without the metabolic defect. N Engl J Med 269:1404–1408
Lenke RR, Levy HL (1980) Maternal phenylketonuria and Hyperphenylalaninaemia. An international survey of the outcome of untreated and treated pregnancies. N Engl J Med 303:1202–1208
Koch R, Hanley W, Levy H et al. (2003) The Maternal Phenylketonuria International Study: 1984–2002. Pediatrics 112:1523–1529
Widaman KF, Azen C (2003) Relation of prenatal phenylalanine exposure to infant and childhood cognitive outcomes: results from the International Maternal PKU Collaborative Study. Pediatrics 112:1537–1543
Levy HL, Guldberg P, Guttler F et al. (2001) Congenital heart disease in maternal phenylketonuria: report from the Maternal PKU Collaborative Study. Pediatr Res 49:636–642
Guttler F, Azen C, Guldberg P et al. (2003) Impact of the phenylalanine hydroxylase gene on maternal phenylketonuria outcome. Pediatrics 112:1530–1533
Koch R, Friedman E, Azen C et al. (2000) The International Collaborative Study of Maternal Phenylketonuria: status report 1998. Eur J Pediatr 159 [Suppl 2]:S156–160
Smith I, Glossop J, Beasley M (1990) Fetal damage due to maternal phenylketonuria: effects of dietary treatment and maternal phenylalanine concentrations around the time of conception (an interim report from the UK Phenylketonuria Register). J Inherit Metab Dis 13:651–657
Galan HL, Marconi AM, Paolini CL et al. (2009) The transplacental transport of essential amino acids in uncomplicated human pregnancies. Am J Obstet Gynecol 200:91 e91–97
Lee PJ, Ridout D, Walter JH et al. (2005) Maternal phenylketonuria: report from the United Kingdom Registry 1978–97. Arch Dis Child 90:143–146
Maillot F, Lilburn M, Baudin J et al. (2008) Factors influencing outcomes in the offspring of mothers with phenylketonuria during pregnancy: the importance of variation in maternal blood phenylalanine. Am J Clin Nutr 88:700–705
Dhondt JL (2010) Lessons from 30 years of selective screening for tetrahydrobiopterin deficiency. J Inherit Metab Dis 33 [Suppl 2]:219–223
Liu KM, Liu TT, Lee NC et al. (2008) Long-term follow-up of Taiwanese Chinese patients treated early for 6-pyruvoyl-tetrahydropterin synthase deficiency. Arch Neurol 65:387–392
Ponzone A, Guardamagna O, Spada M et al. (1993) Differential diagnosis of hyperphenylalaninaemia by a combined phenylalanine-tetrahydrobiopterin loading test. Eur J Pediatr 152:655–661
Hyland K, Surtees RA, Heales SJ et al. (1993) Cerebrospinal fluid concentrations of pterins and metabolites of serotonin and dopamine in a pediatric reference population. Pediatr Res 34:10–14
Smith I, Hyland K, Kendall B (1985) Clinical role of pteridine therapy in tetrahydrobiopterin deficiency. J Inherit Metab Dis 8 [Suppl 1]:39–45
Hyland K (1993) Abnormalities of biogenic amine metabolism. J Inherit Metab Dis 16:676–690
Schuler A, Kalmanchey R, Barsi P et al. (2000) Deprenyl in the treatment of patients with tetrahydrobiopterin deficiencies. J Inherit Metab Dis 23:329–332
Ponzone A, Spada M, Ferraris S et al. (2004) Dihydropteridine reductase deficiency in man: from biology to treatment. Med Res Rev 24:127–150
Porta F, Mussa A, Concolino D et al. (2009) Dopamine agonists in 6-pyruvoyl tetrahydropterin synthase deficiency. Neurology 73:633–637
Ogawa A, Kanazawa M, Takayanagi M et al. (2008) A case of 6-pyruvoyl-tetrahydropterin synthase deficiency demonstrates a more significant correlation of l-dopa dosage with serum prolactin levels than CSF homovanillic acid levels. Brain Dev 30:82–85
Tanaka Y, Kato M, Muramatsu T et al. (2007) Early initiation of ldopa therapy enables stable development of executive function in tetrahydrobiopterin (BH4) deficiency. Dev Med Child Neurol 49:372–376
Jaggi L, Zurfluh MR, Schuler A et al. (2008) Outcome and longterm follow-up of 36 patients with tetrahydrobiopterin deficiency. Mol Genet Metab 93:295–305
Leuzzi V, Carducci CA, Carducci CL et al. (2010) Phenotypic variability, neurological outcome and genetics background of 6-pyruvoyl-tetrahydropterin synthase deficiency. Clin Genet 77:249–257
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2012 Springer-Verlag Berlin Heidelberg
About this chapter
Cite this chapter
Walter, J., Lachmann, R., Burgard, P. (2012). Hyperphenylalaninaemia. In: Saudubray, JM., van den Berghe, G., Walter, J.H. (eds) Inborn Metabolic Diseases. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-642-15720-2_17
Download citation
DOI: https://doi.org/10.1007/978-3-642-15720-2_17
Publisher Name: Springer, Berlin, Heidelberg
Print ISBN: 978-3-642-15719-6
Online ISBN: 978-3-642-15720-2
eBook Packages: MedicineMedicine (R0)